Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innocoll has started dosing in the second of three planned Phase II clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies, to investigate CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers.
Subscribe to our email newsletter
This second Phase II trial will investigate the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers, as defined according to Infectious Disease Society of America guidelines. The third Phase II trial, planned to commence later in April, 2008, will investigate the product for the prevention of infection in diabetic foot ulcers.
Michael Myers, Innocoll’s president and CEO, said: “Since there are currently no topical antibiotics on the market for infected diabetic foot ulcers, we view this Phase II program as a significant step towards treating and potentially preventing this highly serious and widely prevalent complication of diabetes.”